Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia

Alessandro Serretti; Alberto Chiesa; Stefano Porcelli; Changsu Han; Ashwin A. Patkar; Soo Jung Lee; Moon Ho Park; Chi Un Pae

doi:10.1016/j.psychres.2011.02.001

Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia

Alessandro Serretti, Alberto Chiesa, Stefano Porcelli, Changsu Han, Ashwin A. Patkar, Soo Jung Lee, Moon Ho Park, Chi Un Pae

Research output: Contribution to journal › Article › peer-review

42 Citations (Scopus)

Abstract

The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.

Original language	English
Pages (from-to)	26-32
Number of pages	7
Journal	Psychiatry Research
Volume	189
Issue number	1
DOIs	https://doi.org/10.1016/j.psychres.2011.02.001
Publication status	Published - 2011 Aug 30
Externally published	Yes

Bibliographical note

Funding Information:
Acknowledgments We thank all people at the PMMH workshop for their help with the experimental setup, in particular D. Pradal, who conceived and built most of its parts. We thank also X. Benoit-Gonin, M. Vilmay and G. Lemoult for the LabView interfacing, and S. Ramananarivo, V. Raspa, D. Kolomenskiy and G. Spedding for useful discussions. This work was supported by the French National Research Agency through project No. ANR-08-BLAN-0099 and by EADS Foundation through project “Fluids and elasticity in biomimetic propulsion”. M. C. acknowledges financial support from CONACyT and UNAM, México. P. J. acknowledges support from the Charpak Internship Program.

Keywords

Bipolar disorder
Major depression
Schizophrenia
Tryptophan hydroxylase 2

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.psychres.2011.02.001

Cite this

@article{bd1cea4a7cd84dd89ba124d9f4fb85ba,

title = "Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia",

abstract = "The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-{\AA}sberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.",

keywords = "Bipolar disorder, Major depression, Schizophrenia, Tryptophan hydroxylase 2",

author = "Alessandro Serretti and Alberto Chiesa and Stefano Porcelli and Changsu Han and Patkar, {Ashwin A.} and Lee, {Soo Jung} and Park, {Moon Ho} and Pae, {Chi Un}",

note = "Funding Information: Acknowledgments We thank all people at the PMMH workshop for their help with the experimental setup, in particular D. Pradal, who conceived and built most of its parts. We thank also X. Benoit-Gonin, M. Vilmay and G. Lemoult for the LabView interfacing, and S. Ramananarivo, V. Raspa, D. Kolomenskiy and G. Spedding for useful discussions. This work was supported by the French National Research Agency through project No. ANR-08-BLAN-0099 and by EADS Foundation through project “Fluids and elasticity in biomimetic propulsion”. M. C. acknowledges financial support from CONACyT and UNAM, M{\'e}xico. P. J. acknowledges support from the Charpak Internship Program.",

year = "2011",

month = aug,

day = "30",

doi = "10.1016/j.psychres.2011.02.001",

language = "English",

volume = "189",

pages = "26--32",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia

AU - Serretti, Alessandro

AU - Chiesa, Alberto

AU - Porcelli, Stefano

AU - Han, Changsu

AU - Patkar, Ashwin A.

AU - Lee, Soo Jung

AU - Park, Moon Ho

AU - Pae, Chi Un

N1 - Funding Information: Acknowledgments We thank all people at the PMMH workshop for their help with the experimental setup, in particular D. Pradal, who conceived and built most of its parts. We thank also X. Benoit-Gonin, M. Vilmay and G. Lemoult for the LabView interfacing, and S. Ramananarivo, V. Raspa, D. Kolomenskiy and G. Spedding for useful discussions. This work was supported by the French National Research Agency through project No. ANR-08-BLAN-0099 and by EADS Foundation through project “Fluids and elasticity in biomimetic propulsion”. M. C. acknowledges financial support from CONACyT and UNAM, México. P. J. acknowledges support from the Charpak Internship Program.

PY - 2011/8/30

Y1 - 2011/8/30

N2 - The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.

AB - The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.

KW - Bipolar disorder

KW - Major depression

KW - Schizophrenia

KW - Tryptophan hydroxylase 2

UR - http://www.scopus.com/inward/record.url?scp=80051690979&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2011.02.001

DO - 10.1016/j.psychres.2011.02.001

M3 - Article

C2 - 21396719

AN - SCOPUS:80051690979

SN - 0165-1781

VL - 189

SP - 26

EP - 32

JO - Psychiatry Research

JF - Psychiatry Research

IS - 1

ER -

Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this